CINQAERO

This brand name is authorized in Austria, Croatia, Estonia, Finland, France, Ireland, Lithuania, Netherlands, Poland, Spain, UK.

Active ingredients

The drug CINQAERO contains one active pharmaceutical ingredient (API):

1	Reslizumab UNII 35A26E427H - RESLIZUMAB
	Reslizumab is a humanised monoclonal antibody (IgG4, κ) against the human interleukin-5 (IL-5). Reslizumab binds specifically to IL-5 and interferes with IL-5 binding to its cell-surface receptor. IL-5 is a key cytokine responsible for the differentiation, maturation, recruitment and activation of human eosinophils. Reslizumab binds human IL-5 with picomolar affinity blocking its biological function; consequently survival and activity of eosinophils are reduced.
	Read more about Reslizumab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
CINQAERO Concentrate for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
R03DX08		R Respiratory system → R03 Drugs for obstructive airway diseases → R03D Other systemic drugs for obstructive airway diseases → R03DX Other systemic drugs for obstructive airway diseases
Discover more medicines within R03DX08

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1727658, 1744512, 1780297, 1780309
ES	Centro de información online de medicamentos de la AEMPS	1161125001
FI	Lääkealan turvallisuus- ja kehittämiskeskus	163909, 509173
FR	Base de données publique des médicaments	68986222
GB	Medicines & Healthcare Products Regulatory Agency	339800, 348091
LT	Valstybinė vaistų kontrolės tarnyba	1080800, 1083149, 1084987, 1084988
NL	Z-Index G-Standaard, PRK	135097, 143693
PL	Rejestru Produktów Leczniczych	100374200